Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense growth accelerates

Q2 FY2026 income tax expense of $17.83M rose 80.9% year over year, ahead of the +35.5% change in trailing-twelve-month income tax expense. Sequentially, it rose 147.7% from the prior quarter.

Context

  • Income tax expense amounted to 6.5% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +80.9% holds above the trailing-twelve-month pace of +35.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$17.83M+147.7% QoQ
Last fiscal yearDec 2025
$56.38M+21.7% YoY
LTMJun 2026
$59.93M+35.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+80.9%——
1 year+21.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
56.38M USD
Year-over-year change
+21.7%
4-year CAGR
+111.2%

Income Tax Expense vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's LTM Jun 2026 income tax expense of $59.93M is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +35.5% is the highest of 2, against a peer median of -407.7%.
  • Income tax expense amounts to 6.2% of revenue for HRMY.
HRMY Competitors Peer median
Income Tax Expense for HRMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$59.93M +35.5%—6.2%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$1K —+0.0%—
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
CMPSCOMPASS Pathways plcLTM Mar 2026-$5.31M -407.7%——
APMDApnimed, Inc.—— ———
Peer median (excluding HRMY) $0-407.7%+0.0%—

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue305.44M437.86M582.02M714.73M868.45M
Cost of Revenue55.52M83.48M121.24M156.82M198.34M
Gross Profit249.92M354.37M460.79M557.92M670.11M
Gross Margin81.8%80.9%79.2%78.1%77.2%
Research & Development30.37M70.89M76.06M145.83M189.59M
Selling, General & Admin132.03M163.3M192.69M221.27M272.05M
Operating Expenses162.39M234.19M268.76M367.09M461.64M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
EBITDA80.46M146.87M221.51M233.41M255.05M
EBITDA Margin26.3%33.5%38.1%32.7%29.4%
Operating Income87.53M120.19M192.03M190.83M208.47M
Operating Margin28.7%27.4%33.0%26.7%24.0%
Interest Income224K3.13M14.73M18.54M21.92M
Interest Expense24.19M18.8M23.76M17.5M14.65M
Other Income / Expenses(50.1M)(15.5M)(18.63M)978K6.6M
Income Before Tax37.43M104.69M173.4M191.8M215.06M
Pre-Tax Margin12.3%23.9%29.8%26.8%24.8%
Income Tax Expense2.83M(76.78M)44.54M46.31M56.38M
Net Income34.6M181.47M128.85M145.49M158.69M
Net Margin11.3%41.4%22.1%20.4%18.3%
EPS (Basic)0.603.072.172.562.76
EPS (Diluted)0.582.972.132.512.71
Weighted Avg Shares57.53M59.17M59.47M56.89M57.49M
Weighted Avg Shares (Diluted)59.21M61.1M60.37M57.87M58.54M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.